Drug treatment for metabolic dysfunction-associated steatotic liver disease: Progress and direction
Abstract. Metabolic dysfunction-associated steatotic liver disease (MASLD), also called non-alcoholic fatty liver disease, is the most epidemic chronic liver disease worldwide. Metabolic dysfunction-associated steatohepatitis (MASH) is the critical stage of MASLD, and early diagnosis and treatment o...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer
2024-11-01
|
| Series: | Chinese Medical Journal |
| Online Access: | http://journals.lww.com/10.1097/CM9.0000000000003355 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850059414219784192 |
|---|---|
| author | Da Zhou Jiangao Fan Yuanyuan Ji |
| author_facet | Da Zhou Jiangao Fan Yuanyuan Ji |
| author_sort | Da Zhou |
| collection | DOAJ |
| description | Abstract. Metabolic dysfunction-associated steatotic liver disease (MASLD), also called non-alcoholic fatty liver disease, is the most epidemic chronic liver disease worldwide. Metabolic dysfunction-associated steatohepatitis (MASH) is the critical stage of MASLD, and early diagnosis and treatment of MASH are crucial for reducing the incidence of intrahepatic and extrahepatic complications. So far, pharmacotherapeutics for the treatment of MASH are still a major challenge, because of the complexity of the pathogenesis and heterogeneity of MASH. Many agents under investigation have shown impressive therapeutic effects by targeting different key pathways, including the attenuation of steatohepatitis or fibrosis or both. It is notable that thyroid hormone receptor-β agonist, resmetirom has become the first officially approved drug for treating MASH with fibrosis. Other agents such as peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 analogs, and fibroblast growth factor 21 analogs are awaiting approval. This review focuses on the current status of drug therapy for MASH and summarizes the latest results of new medications that have completed phase 2 or 3 clinical trials, and presents the future directions and difficulties of new drug research for MASH. |
| format | Article |
| id | doaj-art-bedb32c4f7d4486ea9428506cdf5e90d |
| institution | DOAJ |
| issn | 0366-6999 2542-5641 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Wolters Kluwer |
| record_format | Article |
| series | Chinese Medical Journal |
| spelling | doaj-art-bedb32c4f7d4486ea9428506cdf5e90d2025-08-20T02:50:53ZengWolters KluwerChinese Medical Journal0366-69992542-56412024-11-01137222687269610.1097/CM9.0000000000003355202411200-00006Drug treatment for metabolic dysfunction-associated steatotic liver disease: Progress and directionDa Zhou0Jiangao Fan1Yuanyuan Ji1 Department of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan University, Shanghai 200032, China3 Department of Gastroenterology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, ChinaAbstract. Metabolic dysfunction-associated steatotic liver disease (MASLD), also called non-alcoholic fatty liver disease, is the most epidemic chronic liver disease worldwide. Metabolic dysfunction-associated steatohepatitis (MASH) is the critical stage of MASLD, and early diagnosis and treatment of MASH are crucial for reducing the incidence of intrahepatic and extrahepatic complications. So far, pharmacotherapeutics for the treatment of MASH are still a major challenge, because of the complexity of the pathogenesis and heterogeneity of MASH. Many agents under investigation have shown impressive therapeutic effects by targeting different key pathways, including the attenuation of steatohepatitis or fibrosis or both. It is notable that thyroid hormone receptor-β agonist, resmetirom has become the first officially approved drug for treating MASH with fibrosis. Other agents such as peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 analogs, and fibroblast growth factor 21 analogs are awaiting approval. This review focuses on the current status of drug therapy for MASH and summarizes the latest results of new medications that have completed phase 2 or 3 clinical trials, and presents the future directions and difficulties of new drug research for MASH.http://journals.lww.com/10.1097/CM9.0000000000003355 |
| spellingShingle | Da Zhou Jiangao Fan Yuanyuan Ji Drug treatment for metabolic dysfunction-associated steatotic liver disease: Progress and direction Chinese Medical Journal |
| title | Drug treatment for metabolic dysfunction-associated steatotic liver disease: Progress and direction |
| title_full | Drug treatment for metabolic dysfunction-associated steatotic liver disease: Progress and direction |
| title_fullStr | Drug treatment for metabolic dysfunction-associated steatotic liver disease: Progress and direction |
| title_full_unstemmed | Drug treatment for metabolic dysfunction-associated steatotic liver disease: Progress and direction |
| title_short | Drug treatment for metabolic dysfunction-associated steatotic liver disease: Progress and direction |
| title_sort | drug treatment for metabolic dysfunction associated steatotic liver disease progress and direction |
| url | http://journals.lww.com/10.1097/CM9.0000000000003355 |
| work_keys_str_mv | AT dazhou drugtreatmentformetabolicdysfunctionassociatedsteatoticliverdiseaseprogressanddirection AT jiangaofan drugtreatmentformetabolicdysfunctionassociatedsteatoticliverdiseaseprogressanddirection AT yuanyuanji drugtreatmentformetabolicdysfunctionassociatedsteatoticliverdiseaseprogressanddirection |